ARCHIVES

DCT Advisors Approve $22 Mil. Set Aside For Interactive R01s Systemic Therapies

This article is from The Cancer Letter archive.

Vol. 18 No. 28 | July 10, 1992

Download PDF Visit The Full Archive

Related Articles

In Brief: James Downing named CEO of St. Jude

June 27, 2014

New Compounds To Treat Gleevec-Resistant CML

January 26, 2007

FDA Proposal On Dissemination of Off-Label Drug Information Doesn’t Go Far Enough, Cancer Groups Say

January 26, 1996

NCCS Networker Volume 2 Issue 1, Winter 1988

January 13, 1988

NCI Moves Ahead With Trials Database, Reporting Studies In Progress At Cancer Centers

July 15, 2011

NCI Has No Intention Of “Dismembering” Groups, Official Says

June 12, 1998